Galmed Pharmaceuticals Restructures Colospan Acquisition to Enhance Shareholder Value and CG-100 Launch

Galmed Pharmaceuticals (GLMD) restructures its acquisition of Colospan Ltd., focusing on protecting shareholder value and prioritizing the commercialization of its CG-100 device. By replacing a $2 million dilutive share payment with an $800,000 cash payment, Galmed aims to boost its operational impact while limiting shareholder dilution. This restructured deal includes an earnout structure that could reach $2 million, contingent upon clear performance metrics tied to the net sales revenue of CG-100, which is expected to establish a strong market presence in Europe and Israel by Q3 2027.

CG-100: A Game Changer in Colorectal Surgery

The CG-100 device represents a major advancement in colorectal surgery, offering a promising solution to mitigate complications associated with anastomotic leaks. With data from four clinical trials involving 97 patients, CG-100 has demonstrated high safety and effectiveness, achieving a remarkable 90% avoidance of stoma creation and a zero percent mortality rate. These results position CG-100 as a crucial tool in enhancing patient outcomes in gastrointestinal surgical procedures.

Strategic Synergy and Future Outlook

CEO Allen Baharaff highlights the strategic synergy anticipated from integrating Colospan’s specialized technologies with Galmed’s extensive experience in gastrointestinal drug development. This acquisition not only strengthens Galmed’s foothold in the GI medical technology landscape but also paves the way for more rapid revenue generation compared to traditional pharmaceuticals.

Financial Stability to Support Growth

Coupled with a robust cash position of $15.6 million reported as of March 31, 2026, Galmed is well-equipped to position CG-100 as a standard method for GI surgeons, aiming for global adoption in the years to come.